Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that enhance the immune response against cancer cells. ICIs are generally well tolerated, although endocrine immune-related adverse events (irAEs) are common. We investigated the risk factors for thyroid irAEs in patients treated with ICIs. Moreover, we evaluated the clinical outcome of subjects who became hypothyroid compared to euthyroid patients.
Higher baseline TSH levels predict early hypothyroidism during cancer immunotherapy / Luongo, C; Morra, R; Gambale, C; Porcelli, T; Sessa, F; Matano, E; Damiano, V; Klain, M; Schlumberger, M; Salvatore, D. - In: JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION. - ISSN 1720-8386. - 44:9(2021), pp. 1927-1933. [10.1007/s40618-021-01508-5]
Higher baseline TSH levels predict early hypothyroidism during cancer immunotherapy
Luongo, C;Morra, R;Gambale, C;Porcelli, T;Sessa, F;Matano, E;Damiano, V;Klain, M;Salvatore, D
2021
Abstract
Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that enhance the immune response against cancer cells. ICIs are generally well tolerated, although endocrine immune-related adverse events (irAEs) are common. We investigated the risk factors for thyroid irAEs in patients treated with ICIs. Moreover, we evaluated the clinical outcome of subjects who became hypothyroid compared to euthyroid patients.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
